




		EMLc	ATC codes: L01DB01
Indication	Anaplastic large cell lymphoma, ALK-negative	ICD11 code: 2A90.B	
INN	Doxorubicin		
Medicine type	Chemical agent		
List type	Complementary		
Formulations	Parenteral > General injections > IV: 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride) ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)		
EML status history	First added in 2023 (TRS 1049)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Tags	Cancer		
Wikipedia	Doxorubicin 		
DrugBank	Doxorubicin 		

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the current listings of cyclophosphamide, cytarabine, dexamethasone, doxorubicin, etoposide, ifosfamide, methotrexate, prednisolone and vinblastine on the complementary list of the EML and EMLc be extended to include the new indication of anaplastic large cell lymphoma (ALCL). These medicines are recognized as part of the standard of care for ALCL. Their benefits and harms were accepted as being well established from use in other indications in children and in adults. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

